In this report, the market is segmented by tool, technology, application, and region. On the basis tool, the synthetic biology market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and xeno-nucleic acids. The chassis organisms segment is expected to grow at the highest rate during the forecast period. The increasing demand for green alternatives (biomass is converted to chemicals using engineered bacteria, yeasts, and other microorganisms) to fossil fuels is a key driver for this segment.
Browse and in-depth TOC on “Synthetic Biology Market”
162 - Tables
32 - Figures
214 - Pages
Get Bundle Reports @ https://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html
According to the new market research report “Synthetic Biology Market” by Tool (Oligonucleotides, Chassis Organisms, Enzymes), Technology (Genome Engineering, NGS, Cloning and Sequencing), Application (Medical (Pharmaceutical, Drug Discovery), Industrial (Renewable Energy)) - Global Forecast to 2022", published by MarketsandMarkets™, The synthetic biology market is expected to reach USD 8.84 Billion by 2022 from an estimated USD 3.57 Billion in 2017, at a CAGR of 19.9%.
Early buyers will receive 10% customization on reports @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=889
By application, the synthetic biology market is segmented into medical (pharmaceutical, drug discovery & therapeutics, and artificial tissue and tissue regeneration), industrial (biofuel & renewable energy, industrial enzymes, and biomaterials & green chemicals), food & agriculture, and environmental (bioremediation and biosensing) applications. The biofuel and renewable energy segment is estimated to grow at the highest CAGR during the forecast period. This high growth rate is attributed to the rising popularity of biofuels and the advantages of using genetically engineered organisms for the synthetic production of biofuels.
Key players in the global synthetic biology market include Thermo Fisher (US), Novozymes (Denmark), Merck KGaA (Germany), Intrexon (US), and Agilent Technologies (US), Amyris (US), GenScript (US), Ginkgo Bioworks (US), Integrated DNA Technologies (US), New England Biolabs (US), Synthetic Genomics (US), and Twist Bioscience (US). These players are increasingly collaborating, and partnering with companies to offer their synthetic oligonucleotides and to develop synthetic organisms.